Clinical studies have found that based on conventional WM treatment, the combined application of Shexiang Baoxin pills can effectively reduce the levels of related hemorheological indexes such as fibrin, plasma viscosity, and whole blood viscosity in CAD patients, improve the levels of serum angiogenesis factors NO, NOS and VEGF, and further promote the establishment of coronary collateral circulation, reduce the incidence frequency and shorten the duration of CAD82. This evidence concerns the gene VEGFA and coronary artery disorder.